Skip to main content
Image of syringe and pipets)

Therapeutic Areas and Products


Our world-leading immunoglobulin (Ig) franchise includes an intravenous and a subcutaneous option and is the cornerstone of the neurology therapeutic area. Our efforts in this area focus on bringing trusted products and technologies to serve patients with a rare and serious neurologic disease, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Key Publications


Subcutaneous Immunoglobulin for maintenance treatment in CIDP (PATH): a randomized, double-blind, placebo-controlled, phase 3 trial
van Schaik, IN et al
Lancet Neurol, 2017

Request | Ask a Question

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH study): study protocol for a randomized controlled trial.
van Schaik, IN et al
Trials, 2016

Request | Ask a Question

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP
Van Schaik, IN et al
Neurol NeuroimmunolNeuroinflamm, 2019

Request | Ask a Question

For U.S. Healthcare Professionals only

The purpose of this CSL Behring Medical Affairs website is to support Healthcare Professionals with scientific information. This website is also a channel for U.S. Healthcare Professionals to submit questions or connect with CSL Behring U.S. Healthcare Professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US Healthcare Professional